The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., & Hasegawa, Y. (2000) · PubMed · Cited by 783
Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery
Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O., & Serabjit-Singh, C. S. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29270-3 · Cited by 662
Newton, D. J., Wang, R. W., & Lu, A. Y. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06500-6 · Cited by 605
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells
Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., & Tokuda, H. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00076-2 · Cited by 568
LeCluyse, E. L. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00135-x · Cited by 477
Taipalensuu, J., Törnblom, H., Lindberg, G., Einarsson, C., Sjöqvist, F., Melhus, H., Garberg, P., Sjöström, B., Lundgren, B., & Artursson, P. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29314-9 · Cited by 444
Role of transport proteins in drug absorption, distribution and excretion
Ayrton, A., & Morgan, P. (2001) · Xenobiotica · doi:10.1080/00498250110060969 · Cited by 421
Gorski, J. C., Jones, D. R., Haehner-Daniels, B. D., Hamman, M. A., O'Mara, E. M., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90146-1 · Cited by 411
Olkkola, K. T., Backman, J. T., & Neuvonen, P. J. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.60 · Cited by 409
Houston, J. B., & Kenworthy, K. E. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15358-5 · Cited by 389
[10] Mechanism-based enzyme inactivators
Silverman, R. B. (1995) · Methods in Enzymology · doi:10.1016/0076-6879(95)49038-8 · Cited by 384
Regulation of the Human CYP2B6 Gene by the Nuclear Pregnane X Receptor
Goodwin, B., Moore, L. B., Stoltz, C. M., McKee, D. D., & Kliewer, S. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12603-x · Cited by 374
Drug Metabolites in Safety Testing
Baillie, T. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9440 · Cited by 371
(1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00268-8 · Cited by 369
Interaction between grapefruit juice and midazolam in humans*
Kupferschmidt, H. H. T., Ha, H. R., Ziegler, W. H., Meier, P. J., & Krähenbühl, S. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90068-3 · Cited by 359
Wu, C.-Y., Benet, L. Z., Hebert, M. F., Gupta, S. K., Rowland, M., Gomez, D. Y., & Wacher, V. J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90168-x · Cited by 356
A potentially hazardous interaction between erythromycin and midazolam
Olkkola, K. T., Aranko, K., Luurila, H., Hiller, A., Saarnivaara, L., Himberg, J.-J., & Neuvonen, P. J. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.25 · Cited by 351
Induction of CYP2C genes in human hepatocytes in primary culture.
Gerbal‐Chaloin, S., Pascussi, J., Pichard‐Garcia, L., Daujat‐Chavanieu, M., Waechter, F., Fabre, J.-M., Carrère, N., & Maurel, P. (2001) · PubMed · Cited by 318
Pharmacogenetics of Warfarin Elimination and Its Clinical Implications
Takahashi, H., & Echizen, H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00003 · Cited by 312
Mayhew, B. S., Jones, D. R., & Hall, S. D. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15182-3 · Cited by 293
Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109797 · Cited by 285
Stresser, D. M., Blanchard, A. P., Turner, S. D., Erve, J. C. L., Dandeneau, A. A., Miller, V. P., & Crespi, C. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13672-0 · Cited by 273
Backman, J. T., Kivistö, K. T., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050420 · Cited by 266
Frye, R. F., Matzke, G. R., Adedoyin, A., Porter, J. A., & Branch, R. A. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90114-4 · Cited by 241
Levy, R. H., Thummel, K. E., Trager, W. F., Hansten, P. D., & Eichelbaum, M. F. (2000) · Cited by 208
Effect of Common Excipients on Caco-2 Transport of Low-Permeability Drugs
Rege, B. D., Yu, L. X., Hussain, A. S., & Polli, J. E. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1127 · Cited by 206
The effect of rifampin administration on the disposition of fexofenadine
Hamman, M. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113697 · Cited by 205
Chang, M., Dahl, M.-L., Tybring, G., Gotharson, E., & Bertilsson, L. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00004 · Cited by 203
Bretschneider, B., Brandsch, M., & Neubert, R. (1999) · Pharmaceutical Research · doi:10.1023/a:1018814627484 · Cited by 202
Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes
LeCluyse, E. L., Madan, A., Hamilton, G., Carroll, K., DeHaan, R., & Parkinson, A. (2000) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/(sici)1099-0461(2000)14:4<177::aid-jbt1>3.0.co;2-4 · Cited by 196
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
Backman, J., Olkkola, K., Aranko, K., Himberg, J., & Neuvonen, P. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04266.x · Cited by 184
Xie, H.-G., Stein, C. M., Kim, R. B., Wilkinson, G. R., Flockhart, D. A., & Wood, A. J. J. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00001 · Cited by 181
Westphal, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.107579 · Cited by 177
Drug Glucuronidation in Clinical Psychopharmacology
Liston, H. L., Markowitz, J. S., & DeVane, C. L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00008 · Cited by 177
Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency
Linder, M. W., Prough, R. A., & Valdes, R. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.2.254 · Cited by 174
Augustijns, P. F., Bradshaw, T. P., Gan, L. S. L., Hendren, R. W., & Thakker, D. R. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.2487 · Cited by 172
Self-citationHeterotropic Cooperativity of Cytochrome P450 3A4 and Potential Drug-Drug Interactions
Tang, W., & Stearns, R. (2001) · Current Drug Metabolism · doi:10.2174/1389200013338658 · Cited by 162
Crespi, C. L., & Miller, V. P. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00028-5 · Cited by 161
Induction of Drug Metabolising Enzymes: Pharmacokinetic and Toxicological Consequences in Humans
Fuhr, U. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038060-00003 · Cited by 154
Tucker, G. T., Houston, J. B., & Huang, S. (2001) · Pharmaceutical Research · doi:10.1023/a:1010994022294 · Cited by 147
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans
Schwarz, U. I., Gramatté, T., Krappweis, J., et al. (2000) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38161 · Cited by 146
Streetman, D. S. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109519 · Cited by 143
Assessment of Liver Metabolic Function: Clinical Implications
Brockmöller, J., & Roots, I. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199427030-00005 · Cited by 139
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
Lin, Y. S., Lockwood, G. F., Graham, M. A., Brian, W. R., Loi, C., Dobrinska, M. R., Shen, D. D., Watkins, P. B., Wilkinson, G. R., Kharasch, E. D., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00006 · Cited by 133
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
Niemi, M., Backman, J. T., Neuvonen, M., Neuvonen, P. J., & Kivistö, K. T. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115822 · Cited by 130
Venkatakrishnan, K., Moltke, L. L., & Greenblatt, D. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29543-4 · Cited by 112
Polymorphisms in UDP Glucuronosyltransferase Genes: Functional Consequences and Clinical Relevance
Mackenzie, P. I., Miners, J. O., & McKinnon, R. A. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.129 · Cited by 106
Chiou, W. L., Chung, S. M., Wu, T. C., & Ma, C. (2001) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp39093 · Cited by 106
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb00001.x · Cited by 102
Gallicano, K., Sahai, J. V., Shukla, V. K., et al. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00987.x · Cited by 100
In vivo modulation of CYP enzymes by quinidine and rifampin
Branch, R. A., Adedoyin, A., Frye, R. F., Wilson, J. W., & Romkes, M. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110561 · Cited by 98
Induction of Cytochrome P450 Enzymes in Cultured Precision-Cut Human Liver Slices
Edwards, R. J., Price, R. J., Watts, P. S., Renwick, A. B., Tredger, J. M., Boobis, A. R., & Lake, B. G. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.282 · Cited by 92
Interaction between midazolam and clarithromycin: comparison with azithromycin.
Yeates, R. A., Laufen, H., & Zimmermann, T. (1996) · PubMed · Cited by 91
High and variable frequencies of CYP2C19 mutations
Kaneko, A., Lum, J. K., Yaviong, J., et al. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00005 · Cited by 90
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050223 · Cited by 85
ROGERS, J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.a101208 · Cited by 84
Meunier, V., Bourrié, M., Julian, B., Marti, E., Guillou, F., Berger, Y., & Fabre, G. (2000) · Xenobiotica · doi:10.1080/004982500406426 · Cited by 83
Induction of cytochrome P450 isoenzymes in cultured precision-cut rat and human liver slices
Lake, B. G., Charzat, C., Tredger, J. M., et al. (1996) · Xenobiotica · doi:10.3109/00498259609046709 · Cited by 82
Pharmacokinetic interaction between rifampin and zidovudine
Burger, D. M., Meenhorst, P. L., Koks, C. H. W., & Beijnen, J. H. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.7.1426 · Cited by 81
Rao, U. S. M., & Scarborough, G. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10165-x · Cited by 78
Assessment of cytochrome P450 activity by a five-drug cocktail approach
Zhu, B. Y., Ouyang, D., Chen, X., Huang, S., Tan, Z., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)92726-2 · Cited by 76
Matsumoto, S.-E., Saito, H., & Inui, K. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22409-0 · Cited by 76
Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
Tang, W., Stearns, R. A., Kwei, G. Y., Iliff, S. A., Miller, R. R., Egan, M. A., Yu, N. X., Dean, D. C., Kumar, S., Shou, M., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35211-5 · Cited by 73
Palmer, J. L., Scott, R. J., Gibson, A., Dickins, M., & Pleasance, S. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01479.x · Cited by 68
DRUG‐MEDIATED INACTIVATION OF CYTOCHROME P450
Murray, M. T. (1997) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1997.tb01228.x · Cited by 64
High and variable frequencies of CYP2C19 mutations
Kaneko, A., Lum, J. K., Yaviong, J., Takahashi, N., Ishizaki, T., Bertilsson, L., Kobayakawa, T., & Björkman, A. (1999) · Pharmacogenetics and Genomics · doi:10.1097/01213011-199910000-00005 · Cited by 58
Zimmermann, T., Yeates, R. A., Laufen, H., et al. (1996) · PubMed · Cited by 55
Störmer, E., Moltke, L. L., & Greenblatt, D. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38970-0 · Cited by 53
Induction of CYP3A isoforms in cultured precisioncut human liver slices
Lake, B. G., Ball, S. E., Renwick, A. B., Tredger, J. M., Kao, J., Beamand, J. A., & Price, R. J. (1997) · Xenobiotica · doi:10.1080/004982597239921 · Cited by 39
Self-citationA pharmacokinetic interaction between roxithromycin and midazolam
Backman, J. T., Aranko, K., Himberg, J., & Olkkola, K. T. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf00196114 · Cited by 38
I.v. fentanyl decreases the clearance of midazolam
Hase, I., Oda, Y., Tanaka, K., et al. (1997) · British Journal of Anaesthesia · doi:10.1093/bja/79.6.740 · Cited by 38
Implications and consequences of enzyme induction on preclinical and clinical drug development
Worboys, P. D., & Carlile, D. J. (2001) · Xenobiotica · doi:10.1080/00498250110054623 · Cited by 37
Adedoyin, A. B., Stiff, D. D., Smith, D. C., Romkes, M., Bahnson, R., Day, R., Hofacker, J., Branch, R. A., & Trump, D. L. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050719 · Cited by 31
Christians, U., Strohmeyer, S. S., Kownatzki, R., Schiebel, H., Bleck, J. S., Greipel, J., Kohlhaw, K., Schottmann, R., & Sewing, K. ‐. (1991) · Xenobiotica · doi:10.3109/00498259109039559 · Cited by 28
Azithromycin does not increase plasma concentrations of oral midazolam.
Backman, J. T., Olkkola, K. T., & Neuvonen, P. J. (1995) · PubMed · Cited by 22
Tsunoda, S. M., VELEZ, R., & Greenblatt, D. J. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)80218-5 · Cited by 8
Lam, Y. W., Ereshefsky, L., Alfaro, C. L., & Miller, M. M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)80105-2 · Cited by 5
Cited by
Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 928
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Walsky, R. L., & Obach, R. S. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.647 · Cited by 507
Self-citationThe Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions
Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B., & Tremaine, L. M. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093229 · Cited by 433
Self-citation
Metadata
- Authors
- Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., Kumar, G., McLeod, J., Obach, R. S., Roberts, S., Roe, A., Shah, A., Snikeris, F., Sullivan, J. T., Tweedie, D., Vega, J. M., Walsh, J., & Wrighton, S. A.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 31
- Issue
- 7
- Pages
- 815-832
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2152964734
- Cited by
- 792
- References
- 78
- FWCI
- 28.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.